MindWalk Posts Third Straight Quarter of Revenue Growth, Shifts to Recurring Platform Model
Event summary
- Q3 revenue hit $4.2M, up 52% YoY, with US revenue doubling to $2.6M.
- Signed first one-year LensAI platform contract with largest enterprise AI client.
- Launched B cell Llama™ nanobody discovery platform targeting $50B+ bispecific market.
- Dengue vaccine program advances after in vivo immunization studies confirm binding.
The big picture
MindWalk's shift to recurring revenue models aligns with broader biotech industry trends toward predictable cash flows. The company's AI-driven approach positions it in a growing segment of biologics discovery, though execution risks remain high as it pivots away from European operations.
What we're watching
- Revenue Model Shift
- Whether the transition from project-based to recurring platform revenue can sustain growth.
- Pipeline Progress
- The pace at which dengue and influenza programs advance toward clinical validation.
- Geographic Focus
- How the North America-centric strategy impacts MindWalk's competitive positioning.